NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ:CDLX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants […]

NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Crocs, Inc. (NASDAQ:CROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/crocs-inc-lawsuit-submission-form?prid=125462&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ATRA.

NEW YORK, NY / ACCESS Newswire / January 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edison International ("Edison International") (NYSE:EIX) concerning possible violations of federal securities laws. On January 12, 2025, the Los Angeles Times published an article, "Officials investigating whether Southern California Edison equipment ignited Hurst

NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Five9, Inc. (NASDAQ:FIVN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/five9-inc-lawsuit-submission-form?prid=125460&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your MGP Ingredients, Inc. (NASDAQ:MGPI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/mgp-ingredients-inc-lawsuit-submission-form?prid=125459&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Sun Communities, Inc. (NYSE:SUI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sun-communities-inc-lawsuit-submission-form?prid=125458&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=125457&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=125456&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

(NASDAQ:PCSA), HANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced the pricing of its “reasonable best efforts” public offering with participation from the Company's Chief Executive Officer,